New study identifies biological mechanism driving therapy resistance in advanced prostate cancer
· Medical Xpressby University of Chicago Medical Center
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
Published in Nature, the study reveals that a specific transfer RNA (tRNA) named tRNAArg (UCU)-1 plays a central role in allowing prostate cancer cells to escape targeted therapies and transition into more aggressive and treatment-resistant forms of the disease. This finding could help researchers develop a way to resensitize resistant tumors to existing therapies.
Treatment resistance in prostate cancer
Prostate cancer, the second-leading cause of cancer death among men in the United States, often depends on androgen receptor signaling for tumor growth. Many tumors initially respond to androgen deprivation therapies and androgen receptor pathway inhibitors like enzalutamide, apalutamide and darolutamide. Over time, some tumors adapt through a process known as lineage plasticity, where cancer cells lose their dependence on androgen signaling and acquire features of neuroendocrine prostate cancer, a form of cancer that is resistant to therapy.
The molecular cues that drive this kind of transformation have remained poorly understood. Using high-resolution RNA sequencing, the research team at the University of Chicago analyzed samples from patients, animal models and prostate cancer cells and found that tRNAArg (UCU)-1, a small noncoding RNA molecule that helps cells make proteins, is consistently depleted as tumors transition from a therapy-responsive to a therapy-resistant state.
"For a long time, tRNAs were considered basic housekeeping units, serving as static transfer vehicles for translating the genetic code during protein synthesis," said Tao Pan, Ph.D., professor of biochemistry and molecular biology at UChicago and co-lead author of the paper.
"In reality, tRNA levels are dynamically tuned to control cell fate, and the low levels of tRNAArg (UCU)-1 act as a molecular switch that allows prostate cancer cells to escape from the treatment and become a more aggressive type of cancer." Pan is also the co-founder of MesoRNA, a UChicago spinout company developing sequencing technologies for small noncoding RNA.
This discovery of the link between tRNAArg (UCU)-1 levels and the translational switch is important because treatment resistance remains one of the biggest challenges in advanced prostate cancer. To understand exactly how this switch works, the research team traced the pathway connecting tRNAArg (UCU)-1 to the cellular machinery that controls prostate cell identity.
Restoring treatment sensitivity
When researchers reduced levels of tRNAArg (UCU)-1 in prostate cancer cells, the cells quickly showed lower levels of androgen receptor, a key driver that many prostate cancer treatments are designed to block. The team looked at what controls tRNAArg (UCU)-1 and found that two proteins, TARDBP and ZSCAN29, help keep this tRNA active.
The researchers also found that tRNAArg (UCU)-1 helps control production of SMARCC2, an important part of cell machinery that helps organize DNA and maintain prostate cancer cells in a treatment-sensitive state. When tRNAArg (UCU)-1 levels drop, SMARCC2 also decreases, disrupting normal cells' identity and making it easier for cancer cells to turn into a more aggressive, therapy-resistant form. Restoring tRNAArg (UCU)-1 or SMARCC2 rescued androgen receptor activity and made resistant cells more responsive to treatment again.
Therapeutic implications and future research
Current treatment options for treatment-resistant neuroendocrine prostate cancer are largely limited to platinum-based chemotherapies, which offer modest survival benefits.
The discovery that tRNA modulation can reverse lineage switching suggests that RNA-targeted therapeutics such as synthetic tRNA mimics or small molecules that enhance tRNAArg (UCU)-1 production could resensitize hard-to-treat tumors to existing, widely available androgen receptor-targeted drugs.
"Unlike DNA mutations where changes are permanent, RNA-regulated processes are reversible," Pan said. "It opens up an unexplored therapeutic landscape focused on modulating RNA dosage and tRNA to overcome drug resistance."
Publication details
Yeon Soo Kim et al., tRNA dosage regulates lineage dependency and resistance in prostate cancer, Nature (2026). DOI: 10.1038/s41586-026-11153-8
Journal information: Nature
Key medical concepts
Clinical categories
OncologyMen's health Provided by University of Chicago Medical Center Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New study identifies biological mechanism driving therapy resistance in advanced prostate cancer (2026, November 7) retrieved 7 November 2026 from https://medicalxpress.com/news/2026-11-biological-mechanism-therapy-resistance-advanced.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.